tiprankstipranks
Trending News
More News >
Biovaxys Technology Corp (BVAXF)
:BVAXF
Advertisement

BioVaxys Technology (BVAXF) Price & Analysis

Compare
32 Followers

BVAXF Stock Chart & Stats


BioVaxys Technology News

BVAXF FAQ

What was Biovaxys Technology Corp’s price range in the past 12 months?
Biovaxys Technology Corp lowest stock price was $0.02 and its highest was $0.06 in the past 12 months.
    What is Biovaxys Technology Corp’s market cap?
    Biovaxys Technology Corp’s market cap is $4.21M.
      When is Biovaxys Technology Corp’s upcoming earnings report date?
      Biovaxys Technology Corp’s upcoming earnings report date is Sep 26, 2025 which is in 55 days.
        How were Biovaxys Technology Corp’s earnings last quarter?
        Biovaxys Technology Corp released its earnings results on Jun 30, 2025. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
          Is Biovaxys Technology Corp overvalued?
          According to Wall Street analysts Biovaxys Technology Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Biovaxys Technology Corp pay dividends?
            Biovaxys Technology Corp does not currently pay dividends.
            What is Biovaxys Technology Corp’s EPS estimate?
            Biovaxys Technology Corp’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Biovaxys Technology Corp have?
            Biovaxys Technology Corp has 291,525,200 shares outstanding.
              What happened to Biovaxys Technology Corp’s price movement after its last earnings report?
              Biovaxys Technology Corp reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Biovaxys Technology Corp?
                Currently, no hedge funds are holding shares in BVAXF

                Company Description

                Biovaxys Technology Corp

                BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.

                BioVaxys Technology (BVAXF) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Innovotech
                Core One Labs
                Tetra Bio-Pharma
                BetterLife Pharma
                Glow LifeTech

                Ownership Overview

                10.05%<0.01%89.95%
                10.05% Insiders
                <0.01% Other Institutional Investors
                89.95% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis